FDA 新增药品类指南文件清单(含 2026 年 3 月至 11 月发布/定稿文件)
Newly Added Guidance Documents | Drugs
美国 FDA 更新药品类新增指南文件清单,涵盖 2026 年 3 月至 11 月发布的多个文件。其中《降低输血传播乙型肝炎病毒风险检测建议》于 11 月 3 日定稿,ICH-Efficacy、ICH-Safety E14 和 S7B 的 QT/QTc 间期延长问答(R1)于 10 月 30 日定稿。
TestingRecommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B VirusFinal11/3/2026ICH-Efficacy, ICH-SafetyE14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1)Final10/30/2026Combination ProductsEssential Drug Delivery Performance Characteristics for Devices Intended to Deliver Drugs and Biological ProductsDraft10/29/2026Technical SpecificationsSubmitting Clinical Trial Data to Evaluate the Ability to Operate a Motor VehicleFinal10/20/2026LabelingRegulatory Considerations for Prescription Drug Use-Related SoftwareFinal10/20/2026BiosimilarsPostapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers Final10/9/2026ICH-EfficacyE2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards CompatibilityFinal10/1/2026CompoundingTemporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for NeonatesFinal9/4/2026Clinical PharmacologyPharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and LabelingDraft9/2/2026Generic Drugs, Drug Competition Action PlanEvaluation of Therapeutic EquivalenceFinal8/24/2026Generic Drugs, Drug Competition Action PlanDetermining Whether to Submit an ANDA or a 505(b)(2) ApplicationDraft8/18/2026Pharmaceutical Quality; Chemistry, Manufacturing, and Controls (CMC)Container Closure Systems for Human Drugs and Biological ProductsDraft8/14/2026Generic Drugs, Drug Competition Action PlanAssessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAsDraft8/3/2026Generic Drugs, Drug Competition Action PlanAssessing Adhesion With Transdermal and Topical Delivery Systems for ANDAsFinal8/3/2026BiosimilarsBiosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent PartsDraft8/3/2026Clinical - MedicalPsychedelic Drugs: Considerations for Clinical InvestigationsFinal7/14/2026Generic Drugs, Drug Competition Action PlanTopical Dermatologic Corticosteroids: In Vivo BioequivalenceFinal7/14/2026Administrative/ProceduralFormal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph DrugsFinal7/14/2026Technical SpecificationsSubmitting Next-Generation Sequencing Data to the Division of Antiviral ProductsFinal7/1/2026Clinical - MedicalMaster Protocols for Drug and Biological Product DevelopmentDraft6/24/2026Clinical - MedicalDemonstrating Substantial Evidence of Effectiveness for Human Drug and Biological ProductsDraft6/24/2026Clinical PharmacologyQuantitative Systems Pharmacology (QSP)-Based Dose Selection for Minimum Anticipated Biological Effect Level (MABEL) in First-in-Human (FIH) TrialsDraft6/24/2026Clinical PharmacologySubmitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of a DrugFinal6/18/2026Generic Drugs, Drug Competition Action PlanForms FDA 3542a and FDA 3542: Questions and AnswersDraft6/15/2026Generic DrugsCertain Postapproval Requirements and Resources for ANDAsFinal6/4/2026Administrative/ProceduralDrug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and AnswersDraft6/3/2026ICH-MultidisciplinaryM15 General Principles for Model-Informed Drug DevelopmentFinal6/3/2026ICH-QualityQ8, Q9, and Q10 Questions and Answers (R5)Final5/29/2026BiopharmaceuticsBioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug ApplicationFinal5/29/2026BiopharmaceuticsStatistical Approaches to Establishing BioequivalenceFinal5/29/2026ICH-MultidisciplinaryM11 Clinical Electronic Structured Harmonised ProtocolFinal5/21/2026Clinical - MedicalOpioid Analgesic Drugs: Considerations for Benefit-Risk Assessment FrameworkDraft5/13/2026Clinical - MedicalDevelopment of Local Anesthetic Drug Products With Prolonged Duration of EffectDraft5/13/2026Clinical - MedicalStimulant Use Disorders: Developing Drugs for TreatmentDraft5/13/2026Clinical - MedicalDevelopment of Non-Opioid Analgesics for Chronic PainDraft5/13/2026Clinical - MedicalDevelopment of Non-Opioid Analgesics for Acute PainDraft5/13/2026Clinical - AntimicrobialClostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and PreventionFinal5/8/2026Clinical - AntimicrobialPulmonary Tuberculosis: Developing Drugs for TreatmentFinal5/8/2026Clinical - MedicalPostapproval Pregnancy Safety StudiesFinal5/8/2026Technical Specifications DocumentSubmitting Continuous Glucose Monitoring Data in Clinical TrialsFinal5/7/2026Pharmaceutical Quality; Chemistry, Manufacturing, and Controls (CMC)Establishing Impurity Specifications for AntibioticsDraft4/20/2026Clinical PharmacologyBioanalytical Method Validation for BiomarkersFinal4/10/2026Pharmacology/ToxicologyGeneral Considerations for the Use of New Approach Methodologies in Drug DevelopmentDraft3/18/2026Generic Drugs, Drug Competition Action Plan, User Fees, Electronic SubmissionsPhysicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAsFinal3/18/2026BiosimilarsQuestions and Answers on Biosimilar Development and the BPCI ActFinal3/10/2026BiosimilarsNew and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4)Draft3/10/2026Current Good Manufacturing Practice (CGMP)Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP InspectionDraft3/9/2026Generic Drugs, Drug Competition Action Plan, Electronic SubmissionsNew Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and AnswersDraft3/3/2026ICH-EfficacyE2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety ReportsFinal3/3/2026ICH-MultidisciplinaryM14 General Principles on Planning, Designing, Analyzing, and Reporting of Non-interventional Studies That Utilize Real-World Data for Safety Assessment of MedicinesFinal3/3/2026Administrative/ProceduralCertification Process for Designated Medical GasesDraft2/11/2026ICH-EfficacyE22 General Considerations for Patient Preference StudiesDraft2/6/2026ICH-MultidisciplinaryM4Q(R2) The Common Technical Document for the Registration of Pharmaceuticals for Human Use: QualityDraft1/21/2026BiostatisticsUse of Bayesian Methodology in Clinical Trials of Drug and Biological ProductsDraft1/12/2026
来源:FDA 官方药品与生物制品信息 · fda.gov